| Ms Kimberly Brooke Mccann, MSN, CPNP-PC, CNS | |
|
130 Riverside Dr, Boulder Creek, CA 95006-9432 | |
| (310) 780-8723 | |
| Not Available |
| Full Name | Ms Kimberly Brooke Mccann |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Pediatrics |
| Location | 130 Riverside Dr, Boulder Creek, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053821553 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0200X | Clinical Nurse Specialist - Pediatrics | 4636 (California) | Secondary |
| 363LP0200X | Nurse Practitioner - Pediatrics | 95007438 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Kimberly Brooke Mccann, MSN, CPNP-PC, CNS 3131 Bagley Ave Apt 7, Los Angeles, CA 90034-2931 Ph: (310) 780-8723 | Ms Kimberly Brooke Mccann, MSN, CPNP-PC, CNS 130 Riverside Dr, Boulder Creek, CA 95006-9432 Ph: (310) 780-8723 |
News Archive
As part of the commitment to providing turn-key innovative solutions for the automotive industry, Bruker's Nano Surfaces Division today announced the release of the Brake Material Screening Module. The module expands the capabilities of the UMT TriboLab, the most widely used platform worldwide for testing friction and wear.
Researchers at the University at Buffalo and the University of Utah are beginning a clinical trial to test whether aspirin can improve a woman's chances of becoming pregnant and of maintaining a pregnancy to term.
Can a high dose of vitamin D administered on admission to hospital improve the condition of patients with moderate or severe COVID-19? The answer is no, according to a Brazilian study published in the Journal of the American Medical Association.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent Office (USPTO) has issued a patent (US 7,704,985) entitled "Treatment of Irritable Bowel Syndrome and Related Bowel Diseases." The patent claims the use of beclomethasone dipropionate (BDP) to treat irritable bowel syndrome (IBS), a painful gastrointestinal condition that affects approximately 15% of the population in the industrialized world.
› Verified 4 days ago